Nitroglycerine use in transcatheter arterial (chemo)embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention

European Radiology

Volumn 22, Issue 10, 2012, Pages 2193-2200

  Liu, Yi Sheng ^a   Chuang, Ming Tsung ^a   Tsai, Yi Shan ^a,b   Tsai, Hong Ming ^a,b   Lin, Xi Zhang ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Dual energy CT; Enhanced permeability retention; Hepatocellular carcinoma; Nitroglycerine; Transarterial chemoembolization

Indexed keywords

DOXORUBICIN; GELFOAM; GLYCERYL TRINITRATE; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; NITROGLYCERIN; TOMOGRAPHY, X-RAY COMPUTED; VASODILATOR AGENTS;

EID: 84867271147     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2484-4     Document Type: Article

References (26)

1. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127:S5-S16
2. Thomas MB, Jaffe D, Choti MM et al (2010) Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28:3994-4005
3. National Cancer Institute (2011) Adult primary liver cancer treatment (PDQ®) health profession version. http://www.cancer.gov/cancertopics/types/ liver. Accessed 5 Nov 2011
4. Rougier P, Mitry, Barbare JC, Taieb J (2007) Hepatocellular carcinoma (HCC): An update. Semin Oncol 34:S12-S20
5. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF (2002) Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 13:S211-S221
6. Lencioni R (2010) Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology 78:107-112
7. Konno T, Maeda H, Iwai K et al (1983) Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report. Eur J Cancer Clin Oncol 19:1053-1065
8. Konno T, Maeda H, Iwai K et al (1984) Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54:2367-2374
9. Jinno K, Moriwaki S, Tanada M et al (1992) Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 31:S7-S12
10. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392
11. Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-Targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47-61
12. Maeda H (2001) SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev 46:169-185
13. Nagamitsu A, Greish K, Maeda H (2009) Elevating blood pressure as a strategy to increase tumor-Targeted delivery of macromolecular drug SMANCS: Cases of advanced solid tumors. Jpn J Clin Oncol 9:756-766
14. Maeda H, Noguchi Y, Sato K, Akaike T (1994) Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 85:331-334
15. Wu J, Akaike T, Maeda H (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res 58:159-165
16. Seki T, Fang J, Maeda H (2009) Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 100:2426-2430
17. Stoeckelhuber BM, Suttmann I, Stoeckelhuber M, Kueffer G (2003) Comparison of the vasodilating effect of nitroglycerin, verapamil, and tolazoline in hand angiography. J Vasc Interv Radiol 14:749-754
18. Bilbao R, Bustos M, Alzuguren P, Pajares et al (2000) A bloodtumor barrier limits gene transfer to experimental liver cancer: The effect of vasoactive compounds. Gene Ther 7:1824-1832
19. Fang J, Nakamura H, Maeda H (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136-151
20. Pleguezuelo M, Marelli L, Misseri M et al (2008) TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 8:1623-1641
21. Graser A, Johnson TR, Chandarana H, Macari M (2009) Dual energy CT: Preliminary observations and potential clinical applications in the abdomen. Eur Radiol 19:13-23
22. Zhang LJ, Peng J, Wu SY et al (2010) Liver virtual non-enhanced CT with dual-source, dual-energy CT: A preliminary study. Eur Radiol 20:2257-2264
23. Oliveri RS, Wetterslev J, Gluud C (2011) Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 16:CD004787
24. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25
25. Marelli L, Shusang V, Buscombe JR et al (2009) Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 50:871-877
26. Hou YC, Janczuk A, Wang PG (1999) Current trends in the development of nitric oxide donors. Curr Pharm Des 5:417-441